anus neoplasms

Summary

Summary: Tumors or cancer of the ANAL CANAL.

Top Publications

  1. ncbi Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus
    Francine Walker
    Department of Pathology, Institut de la Santé et de la Recherche Médicale Unité773, Hopital Bichat Claude Bernard, 75018 Paris, France
    Hum Pathol 40:1517-27. 2009
  2. ncbi Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas 77030, USA
    JAMA 299:1914-21. 2008
  3. ncbi Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis
    Hugo De Vuyst
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Int J Cancer 124:1626-36. 2009
  4. ncbi Anal cancer: the end of the road for neoadjuvant chemoradiotherapy?
    Rob Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    J Clin Oncol 26:3669-71. 2008
  5. ncbi The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy
    D C Weber
    Radiation Oncology Department of the University Hospital, Geneva, Switzerland
    Int J Radiat Oncol Biol Phys 50:675-80. 2001
  6. ncbi High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study
    D Peiffert
    Centre Alexis Vautrin, Nancy, France
    Ann Oncol 12:397-404. 2001
  7. ncbi Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)
    O Matzinger
    EORTC Headquarters, Brussels, Belgium
    Eur J Cancer 45:2782-91. 2009
  8. ncbi Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions
    Brooke E Hoots
    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599 7400, USA
    Int J Cancer 124:2375-83. 2009
  9. ncbi ACT II: the second UK phase III anal cancer trial
    R James
    Clin Oncol (R Coll Radiol) 17:364-6. 2005
  10. ncbi Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro
    H Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Huis, Amsterdam, The Netherlands
    J Clin Oncol 15:2040-9. 1997

Detail Information

Publications188 found, 100 shown here

  1. ncbi Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus
    Francine Walker
    Department of Pathology, Institut de la Santé et de la Recherche Médicale Unité773, Hopital Bichat Claude Bernard, 75018 Paris, France
    Hum Pathol 40:1517-27. 2009
    ..The finding that EGFR, c-Met, and VEGFR1 involved in carcinogenesis are well-represented and coexpressed in anal cancers, especially in HIV-positive population, suggests possible novel targeted treatments for anal diseases...
  2. ncbi Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas 77030, USA
    JAMA 299:1914-21. 2008
    ..Chemoradiation as definitive therapy is the preferred primary therapy for patients with anal canal carcinoma; however, the 5-year disease-free survival rate from concurrent fluorouracil/mitomycin and radiation is only approximately 65%...
  3. ncbi Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis
    Hugo De Vuyst
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Int J Cancer 124:1626-36. 2009
    ..This proportion would be similar for the corresponding high-grade lesions of the vagina and anus, but higher for VIN2/3 (75%) than for vulvar carcinoma...
  4. ncbi Anal cancer: the end of the road for neoadjuvant chemoradiotherapy?
    Rob Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    J Clin Oncol 26:3669-71. 2008
  5. ncbi The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy
    D C Weber
    Radiation Oncology Department of the University Hospital, Geneva, Switzerland
    Int J Radiat Oncol Biol Phys 50:675-80. 2001
    ..The present analysis suggests that shortening the gap contributes to optimizing LRC. Gaps longer than 5 weeks correlated with poorer LRC, with especially unsatisfactory results observed in younger patients...
  6. ncbi High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study
    D Peiffert
    Centre Alexis Vautrin, Nancy, France
    Ann Oncol 12:397-404. 2001
    ..To analyse toxicity and response to a new scheme of neoadjuvant chemotherapy (CT) and concomitant radiochemotherapy (RT-CT) for locally advanced anal canal squamous-cell carcinoma (ACC)...
  7. ncbi Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)
    O Matzinger
    EORTC Headquarters, Brussels, Belgium
    Eur J Cancer 45:2782-91. 2009
    ..To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with MMC and fluorouracil (5-FU)...
  8. ncbi Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions
    Brooke E Hoots
    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599 7400, USA
    Int J Cancer 124:2375-83. 2009
    ..If ongoing clinical trials show efficacy in preventing anal HPV infection and associated anal lesions, prophylactic HPV vaccines may play an important role for the primary prevention of these cancers in both genders...
  9. ncbi ACT II: the second UK phase III anal cancer trial
    R James
    Clin Oncol (R Coll Radiol) 17:364-6. 2005
  10. ncbi Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro
    H Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Huis, Amsterdam, The Netherlands
    J Clin Oncol 15:2040-9. 1997
    ....
  11. ncbi Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection
    S Hocht
    Abteilung Strahlentherapie, Universitätsklinikum Benjamin Franklin der Freien Universität Berlin, Germany
    Acta Oncol 36:799-802. 1997
    ..No excessive acute reactions were seen. Because of the short follow-up, late reactions and local control are not yet evaluable...
  12. ncbi Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study
    M Flam
    University of California, San Francisco, Fresno, USA
    J Clin Oncol 14:2527-39. 1996
    ....
  13. ncbi Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy
    Robert P Akbari
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Dis Colon Rectum 47:1136-44. 2004
    ..persistence) after chemoradiation (when salvage is potentially curative), absence of nodal disease at salvage, and negative margins. Salvage inguinal lymph node dissection after failed chemoradiation therapy also is potentially curative...
  14. ncbi Smoking-related DNA adducts in anal epithelium
    David H Phillips
    Institute of Cancer Research, Brookes Lawley Building, Cotswold Road, Sutton SM2 5NG, UK
    Mutat Res 560:167-72. 2004
    ..00001, Fisher's exact test). These results indicate that components of tobacco smoke inflict genotoxic damage in the anal epithelium of smokers and provide a plausible mechanism for a causal association between smoking and anal cancer...
  15. ncbi [Anorectal melanoma. A rare and highly malignant tumor entity of the anal canal]
    B M Helmke
    Pathologisches Institut, Universitat Heidelberg
    Pathologe 25:171-7. 2004
    ..The poor long-term prognosis of anorectal melanomas correlates with their advanced tumor size and depth of infiltration at diagnosis. The overall 5-year survival rates range between <5 and 22% in different series...
  16. ncbi Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer
    Julie K Schwarz
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 71:180-6. 2008
    ..To evaluate the response to therapy for anal carcinoma using post-therapy imaging with positron emission tomography (PET)/computed tomography and F-18 fluorodeoxyglucose (FDG) and to compare the metabolic response with patient outcome...
  17. ncbi Cancer of the anal canal
    Matthew A Clark
    Department of General Surgery, Middlemore Hospital, Otahuhu, Auckland, New Zealand
    Lancet Oncol 5:149-57. 2004
    ..Future challenges will be influenced by an increasing incidence due to human papillomavirus and HIV infection, more accurate characterisation and treatment of early (in situ) disease, and optimisation of chemoradiation regimens...
  18. ncbi [Radiotherapy of carcinomas of the anal canal. Tenon Hospital experience]
    E Touboul
    service d oncologie radiothérapie, Hopital Tenon, AP HP, 4, rue de la Chine, 75020 Paris, France
    Cancer Radiother 7:91s-99s. 2003
    ..We report the Tenon hospital experience since 1972 concerning the long term results after radiation therapy, the modifications of the radiation technique, and the evolution of treatment strategy...
  19. ncbi Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network
    Yazid Belkacemi
    Radiation Therapy, Oscar Lambret Center, Lille, France
    Int J Radiat Oncol Biol Phys 56:1274-83. 2003
    ..The current standard treatment consists of abdominoperineal resection (APR). The aim of this Rare Cancer Network study was to evaluate the prognostic factors and outcome after the three most commonly used treatment approaches...
  20. ncbi Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy
    Loren K Mell
    Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 70:1431-7. 2008
    ....
  21. ncbi Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal
    S Gretschel
    Department of Surgery and Surgical Oncology, Charite, Universitatsmedizin Berlin, Campus Buch, Robert Rossle Klinik, HELIOS Klinikum Berlin, Berlin, Germany
    Eur J Surg Oncol 34:890-4. 2008
    ..Inguinal sentinel lymph node biopsy (SLNB) can be used to select patients appropriately for inguinal radiation. The study evaluates the efficiency and clinical impact of SLNB...
  22. ncbi Gastrointestinal stromal tumor of the anus
    G Y M Tan
    Department of Colorectal Surgery, Singapore General Hospital, Singapore
    Tech Coloproctol 7:169-72. 2003
    ..Oncologic resection and protracted follow-up must factor in their predilection for late recurrence and metastatic spread. The role of adjuvant therapy with STI571 here remains to be clearly defined...
  23. ncbi Carcinoma of the anal canal: a local experience and review of the literature
    Shirley Wong
    Department of Medical Oncology, Royal Melbourne Hospital, Victoria, Australia
    ANZ J Surg 74:541-6. 2004
    ..The aim of the present study is to determine how widely the combined modality approach has been adopted in routine clinical practice and what outcomes are achieved in this setting...
  24. ncbi Anorectal amelanotic melanoma
    A Hillenbrand
    Department of General, Visceral, and Transplantation Surgery, University of Ulm, Ulm, Germany
    Colorectal Dis 10:612-5. 2008
    ..Anorectal melanoma is a rare, highly malignant tumour with a poor 5 year survival of 10%. Most anorectal melanomas have gross and/or histologic pigmentation, however about 30% of anorectal melanomas are amelanotic...
  25. ncbi Surgical management of primary anorectal melanoma
    P Pessaux
    Department of Surgery, Comprehensive Cancer Centre, Institut Gustave Roussy, Villejuif, France
    Br J Surg 91:1183-7. 2004
    ..CONCLUSION: Anorectal melanoma is a rare disease with a poor prognosis. Wide local excision is recommended as primary therapy if negative resection margins can be achieved...
  26. ncbi FDG-PET/CT in the evaluation of anal carcinoma
    Shane E Cotter
    Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
    Int J Radiat Oncol Biol Phys 65:720-5. 2006
    ..FDG-PET/CT detects substantially more abnormal inguinal lymph nodes than are identified by standard clinical staging with CT and physical examination...
  27. ncbi Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification
    Gustavo Alvarez
    Lauren V Ackerman Laboratory of Surgical Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110-1093, USA
    Mod Pathol 19:942-9. 2006
    ..These observations may have important therapeutic implications since EGFR-based targeted therapies have shown promise for other malignant neoplasms...
  28. ncbi Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 63:354-61. 2005
    ..Compared with historical controls, local control is not compromised despite efforts to increase conformality and reduce normal structure dose...
  29. ncbi [Anal cancer in Iceland 1987-2003. A population based study]
    Halla Vietharsdóttir
    Department of Surgery, Iceland University Hospital, Hringbraut, 101 Reykjavik, Iceland
    Laeknabladid 92:365-72. 2006
    ..Anal cancer is a rare disease. The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival...
  30. ncbi Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal
    Thomas G Trautmann
    Southeast Radiation Oncology, Charlotte, NC, USA
    Mol Imaging Biol 7:309-13. 2005
    ..We investigated the utility of positron emission tomography (PET) with 2-deoxy-2[F-18]fluoro-D-glucose (FDG) in the staging and determination of response to CMT...
  31. ncbi Factors affecting survival in patients with anal melanoma
    Yale D Podnos
    Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, California 91010, USA
    Am Surg 72:917-20. 2006
    ..Anal melanoma remains an uncommon but lethal disease. Extent of disease correlates with overall survival. Survival is improving, but the use and extent of operation are not associated with improved overall survival...
  32. ncbi Response of stage IV anal mucosal melanoma to chemotherapy
    Jen Jen Yeh
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 6:438-9. 2005
  33. ncbi Wide local excision or abdominoperineal resection as the initial treatment for anorectal melanoma?
    John T Droesch
    Department of Surgery, University of Washington, 1959 N E Pacific St, Box 356410, Seattle, WA 98195 6410, USA
    Am J Surg 189:446-9. 2005
    ..Anorectal melanoma (AM) is a rare tumor with a poor prognosis. Treatment with abdominoperineal resection (APR) over wide local excision (WLE) is still debated. This study aimed to compare median survival of WLE and APR in patients with AM...
  34. ncbi Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy
    Te Vuong
    Department of Radiation Oncology, McGill University Health Centre, Quebec, Canada
    Int J Radiat Oncol Biol Phys 67:1394-400. 2007
    ....
  35. ncbi Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome
    Andreas Meyer
    Department of Radiation Oncology, Medical School Hannover, Hannover, Germany
    Acta Oncol 45:728-35. 2006
    ..762), respectively. Chemoradiotherapy with short individualised treatment interruptions seems to be feasible with acceptable acute or late toxicities. Treatment is highly effective in terms of local control and colostomy-free survival...
  36. ncbi Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols
    Per J Nilsson
    Centre of Gastrointestinal Disease, Ersta Hospital, Stockholm, Sweden
    Int J Radiat Oncol Biol Phys 61:92-102. 2005
    ..The use of neoadjuvant chemotherapy has been infrequently reported in the literature. This study presents results from a large population-based series and provides comparisons between different treatments...
  37. ncbi Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 25:4581-6. 2007
    ..To report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT)...
  38. ncbi Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy
    R Graf
    Center of Radiation Medicine, Campus Virchow Clinic, , Humboldt University, Berlin, Germany
    Oncology 65:14-22. 2003
    ....
  39. ncbi Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study
    Te Vuong
    Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada
    Int J Radiat Oncol Biol Phys 56:823-31. 2003
    ..To evaluate the feasibility of delivering conformal radiotherapy (RT) and concurrent chemotherapy without a mandatory break in patients with anal canal carcinoma...
  40. ncbi Carcinoma of the anus: strategies in management
    Natia Esiashvili
    Emory University School of Medicine, Department of Radiation Oncology, Atlanta, Georgia, USA
    Oncologist 7:188-99. 2002
    ..Ongoing studies attempt to define an optimal treatment regimen that yields a higher cure rate while minimizing toxicity. We review the etiology, epidemiology, and treatment regimens for anal cancer...
  41. ncbi Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status
    Nadine Lukan
    III Medizinische Klinik, Universitatsmedizin Mannheim, Mannheim, Deutschland
    Oncology 77:293-9. 2009
    ..Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far...
  42. ncbi Biochemotherapy in patients with metastatic anorectal mucosal melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas 77030, USA
    Cancer 100:1478-83. 2004
    ..Patients with metastatic anorectal melanoma generally have an unfavorable prognosis, but no effective systemic therapy has been reported...
  43. ncbi Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement
    Joseph C Hodges
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 75:791-4. 2009
    ....
  44. ncbi A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy
    Kiran Devisetty
    Department of Radiation and Cellular Oncology, University of Chicago, IL, USA
    Radiother Oncol 93:298-301. 2009
    ..For V(30)>450 cc and < or =450 cc, acute GI toxicity was 33% and 8%, respectively (p=0.003)...
  45. ncbi Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome
    R J Myerson
    Radiation Oncology Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    Radiother Oncol 61:15-22. 2001
    ..Because of the occurrence of additional malignancy, patients with anal cancer should receive general oncologic screening in long-term follow-up...
  46. ncbi The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer
    E de Winton
    Department of Oncology, Royal United Hospital, Bath, UK
    Br J Cancer 100:693-700. 2009
    ..9%) and 55.3% (95% CI: 23.3-83.4%), respectively. FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients...
  47. ncbi The evolving treatment of anal cancer: How are we doing?
    M H Whiteford
    Department of Surgery, Oregon Health Sciences University, Portland, OR, USA
    Arch Surg 136:886-91. 2001
    ..The adaptation of new techniques in treatment of epidermoid carcinoma of the anal canal during the past 3 decades has improved clinical outcomes...
  48. ncbi Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy
    A S Allal
    Division of Radiation Oncology, University Hospital of Geneva, Switzerland
    Br J Cancer 80:1588-94. 1999
    ..Moreover, the subset of patients who presented with severe complications and/or anal dysfunction showed poorer scores in most scales...
  49. ncbi Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals
    I Sobhani
    Department of Coloproctology, Hopital Bichat Claude Bernard, Paris, France
    Gastroenterology 120:857-66. 2001
    ..We determined the prevalence of anal dysplasia and cancer in patients with anal canal condyloma with respect to human immunodeficiency virus (HIV) status, immunity status, and human papillomavirus types...
  50. ncbi Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature
    J P Gerard
    Department of Radiotherapy Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
    Cancer 92:77-84. 2001
    ....
  51. ncbi Can the radiation dose to CT-enlarged but FDG-PET-negative inguinal lymph nodes in anal cancer be reduced?
    Sabine Kathrin Mai
    Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Germany
    Strahlenther Onkol 185:254-9. 2009
    ..To investigate whether a dose reduction to CT-enlarged but FDG-PET-negative (([(18)F]-fluoro-2-deoxy-D-glucose positron emission tomography) inguinal lymph nodes in radiochemotherapy of anal cancer is safe...
  52. ncbi Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study
    T Bjørge
    Department of Pathology, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Br J Cancer 87:61-4. 2002
    ..This study provides prospective epidemiological evidence of an association between infection with HPV 16 and 18 and anal and perianal skin cancer...
  53. ncbi Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta
    A Ulmer
    , , Liebermeisterstr. 25, , Germany
    Melanoma Res 12:395-8. 2002
    ....
  54. ncbi Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases
    Satoshi Ishizone
    Department of Surgery, Shinshu University School of Medicine, 3 1 1 Asahi, Matsumoto, 390 8621, Japan
    Int J Colorectal Dis 23:1257-62. 2008
    ..We also review the present five cases along with 74 other Japanese cases reported between 1997 and 2006 and discuss the role of surgery in the treatment of AMM...
  55. ncbi Screening for anal dysplasia associated with human papillomavirus
    Wm Christopher Mathews
    University of California San Diego Medical Center, USA
    Top HIV Med 11:45-9. 2003
    ..This article summarizes a presentation given by Wm. Christopher Mathews, MD, MSPH, at the November 2002 International AIDS Society-USA course in San Diego...
  56. ncbi Assessing the impact of FDG-PET in the management of anal cancer
    Brandon T Nguyen
    Radiation Oncology Centre, Austin Health, Vic, Australia
    Radiother Oncol 87:376-82. 2008
    ..To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease...
  57. ncbi Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastr
    J F Bosset
    Radiotherapy Department, Besancon University Hospital, Besancon, France
    Eur J Cancer 39:45-51. 2003
    ..The 22953 scheme is feasible and the results are promising. This is now considered as the new standard scheme by the EORTC...
  58. ncbi Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings
    Mayura Nathan
    Department of Sexual Health, Homerton University Hospital NHS Foundation Trust, London E9 6SR, UK
    AIDS 24:373-9. 2010
    ..The success of cervical cytology in screening for cervical neoplasia has led to the concept of anal cytology screening for anal neoplasia. Our objective is to study the performance of anal cytology as a screening tool...
  59. ncbi Tobacco smoking as a risk factor in anal carcinoma: an antiestrogenic mechanism?
    M Frisch
    Department of Epidemiology Research, Danish Epidemiology Science Center, Statens Serum Institut, Copenhagen
    J Natl Cancer Inst 91:708-15. 1999
    ..Smoking was recently suggested to increase the risk of anal cancer more in premenopausal women than in postmenopausal women. Thus, we used our population-based anal cancer case-control study in Denmark and Sweden to test this hypothesis...
  60. ncbi Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus
    Peter V Chin-Hong
    Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, CA 94143 0512, USA
    Clin Infect Dis 35:1127-34. 2002
    ..Treatment for AIN remains challenging, but AIN is easier to treat when the lesions are small, and it is likely that a screening program would identify affected individuals at an earlier stage of disease...
  61. ncbi Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors, and toxicity
    Sabine K Mai
    Department of Radiation Oncology, University Medical Center Mannheim, Germany
    Onkologie 31:251-7. 2008
    ..This retrospective study evaluated the efficacy, prognostic factors, and toxicity of combined radiochemotherapy for anal cancer...
  62. ncbi Sentinel lymph node biopsy for squamous cell carcinoma of the anal canal
    Philippa Rabbitt
    University of Adelaide Department of Surgery, The Queen Elizabeth Hospital, South Australia, Australia
    ANZ J Surg 72:651-4. 2002
    ..The fourth patient had a sentinel node mapped to a meso-rectal node. This was not sampled. CONCLUSIONS: The application of this effective technique will allow accurate staging of anal cancers to better plan future treatment regimes...
  63. ncbi Management of anal cancer in the HIV-positive population
    John Kauh
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Oncology (Williston Park) 19:1634-8; discussion 1638-40, 1645 passim. 2005
    ..Continued studies and phase III trials will be needed to test new treatment strategies in HIV-infected patients with squamous cell cancer of the anus to determine which treatment protocols provide the greatest benefits...
  64. ncbi Cutaneous malignancy and human immunodeficiency virus disease
    Karl Wilkins
    Department of Dermatology, University of California San Francisco, California, USA
    J Am Acad Dermatol 54:189-206; quiz 207-10. 2006
    ..LEARNING OBJECTIVE: At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with HIV...
  65. ncbi Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities
    Scott Edelman
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Int J Radiat Oncol Biol Phys 66:206-11. 2006
    ..We report toxicity and survival data of human immunodeficiency virus (HIV)-infected men with anal carcinoma treated with combined modality therapy (CMT) of radiotherapy and concurrent chemotherapy...
  66. ncbi Anus-preservation treatment for anal cancer: retrospective analysis at a single institution
    Yi Wei Chen
    Cancer Center, Taipei Veterans General Hospital and Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China
    J Surg Oncol 96:374-80. 2007
    ..To evaluate anus-preservation treatment for anal cancer...
  67. ncbi The bottom line: outcomes after conservation treatment in anal cancer
    M K Dwyer
    Department of Radiation Oncology, Westmead Hospital, Westmead, North South Wales, Australia
    Australas Radiol 50:46-51. 2006
    ..Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation. Further studies are in progress to determine the optimal chemoradiation protocol...
  68. ncbi [Challenging conversation with a patient about the change in treatment strategy from a curative to a palliative setting]
    Heinrich Kiss
    Interne Abteilung mit Palliativstation, Krankenhaus Oberwart, Osterreich
    Wien Med Wochenschr 156:324-6. 2006
    ..This case shows the typical problems of a physician-patient relationship in an oncologic clinic and emphasizes the importance of integrating medical with psychosocial care...
  69. ncbi Anal cancer: current and future methodology
    Cathy Eng
    University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Houston, TX 77030, USA
    Cancer Invest 24:535-44. 2006
    ..Novel approaches currently are underway in this select patient population and will be addressed for the purposes of this manuscript...
  70. ncbi Lipodermatosclerosis as a form of vascular compromise-associated radiation recall dermatitis: case report and a review of literature
    Novie Sroa
    College of Medicine and Public Health, Ohio State Universitym Columbus, Ohio, USA
    J Cutan Pathol 33:55-9. 2006
    ..This is the first case providing evidence of the causative role of 5-fluorouracil and cisplatin in potentially inducing RRD...
  71. ncbi Squamous-cell carcinoma of the anal canal: predictors of treatment outcome
    Ramin Roohipour
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 51:147-53. 2008
    ..The incidence of anal canal squamous-cell carcinoma is increasing. Limited data exist on predictors of treatment failure. This study was designed to identify predictors for relapse/persistence after first-line therapy...
  72. ncbi EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer
    Rob Glynne-Jones
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Middlesex, United Kingdom
    Int J Radiat Oncol Biol Phys 72:119-26. 2008
    ..This phase II trial aimed to determine the feasibility, toxicity, and efficacy of capecitabine, MMC and radiotherapy (RT) in anal cancer patients...
  73. ncbi Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281)
    Neal J Meropol
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3229-34. 2008
    ....
  74. ncbi Anal human papillomavirus testing with Digene's hybrid capture 2 using two different sampling methods
    Florian Roka
    Department of Dermatology, Division of General Dermatology, Medical University Vienna, Waehringer Guertel 1820, Vienna, Austria
    Dis Colon Rectum 51:62-6. 2008
    ..The purpose of this study was to determine the usefulness of a human papillomavirus-DNA detection test to detect human papillomavirus-associated disease and to compare two different methods of sample collection...
  75. ncbi Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database
    Shehnaz K Hussain
    Center for Family and Community Medicine, Karolinska Institute, Huddinge, Sweden
    Int J Cancer 122:1873-8. 2008
    ..These data suggest that common host factors exist among individuals affected with anogenital and upper aerodigestive tract cancers...
  76. ncbi Prevalence status and association with human papilloma virus of anal squamous proliferative lesions in a patient sample in Taiwan
    Tsen Fang Tsai
    Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China
    Sex Transm Dis 35:721-4. 2008
    ..The objectives of the study were to investigate the HPV prevalence of anal squamous proliferative lesion in Taiwan...
  77. ncbi Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma
    Heena Patel
    Colorectal Cancer Genetics, Institute for Cell and Molecular Sciences, Blizard Building, Barts and The London, Queen Mary s School of Medicine and Dentistry, 4 Newark St, Whitechapel E1 2AT, United Kingdom
    Int J Cancer 121:2668-73. 2007
    ..04, p = 0.01, respectively). We propose that activation of AKT, possibly through the PI3K-AKT pathway, is an important component of ASCC tumorigenesis that contributes to MDM2 and TP53 accumulation in the nucleus...
  78. ncbi Anal intraepithelial neoplasia and anal cancer in dermatological practice
    Asoka Herat
    Skin and Cancer Foundation, Darlinghurst, New South Wales, Australia
    Australas J Dermatol 48:143-53; quiz 154-5. 2007
    ..In view of recent developments in the understanding of this condition, this article reviews the current understanding of anal intraepithelial neoplasia and its treatment from a dermatological perspective...
  79. ncbi Outcomes of salvage surgery for squamous cell carcinoma of the anal canal
    Dan E Schiller
    Department of Surgery, Mount Sinai Hospital, University of Toronto, Suite 1224, 600 University Avenue, M5G 1X5, Toronto, Ontario, Canada
    Ann Surg Oncol 14:2780-9. 2007
    ..The literature regarding SS is limited by small patient numbers and/or heterogeneous treatment protocols. We report on a large series of patients initially treated with chemoradiation at a major referral center...
  80. ncbi Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour
    M G Tytherleigh
    Department of Surgery, Wexham Park Hospital, Slough, Berkshire, SL2 4HL, UK
    Surgeon 4:378-83. 2006
    ..Chemoradiation remains the mainstay of treatment for anal cancers but has not been routinely employed in the management of the BLT without squamous cell carcinoma transformation...
  81. ncbi [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]
    E Deniaud-Alexandre
    , , APHP, 4, rue de la Chine, 75970 Paris Cedex 20, France
    Cancer Radiother 10:572-82. 2006
    ..For patients with T3 or T4 lesion and tumor regression <or=50% after the first course of radiation therapy, surgical non conservative treatment should be discussed...
  82. ncbi Human papillomavirus (HPV), DNA aberrations and cell cycle progression in anal squamous cell carcinoma patients
    Nongnit Laytragoon-Lewin
    Department of Oncology, Rudbeck Laboratory, Uppsala University Hospital, Sweden
    Anticancer Res 27:4473-9. 2007
    ..Human papillomavirus (HPV) infections of the genital tract are sexually transmitted and prevalent worldwide. In this study, the role of HPV in 72 patients with anal squamous cell carcinoma was investigated...
  83. ncbi [Malignant transformation of perianal Buschke-Löwenstein tumor. Extensive abdominoperineal rectum excision and reconstruction with transpelvic myocutaneous rectus abdominis muscle flap]
    R Dolanc
    Departement Chirurgie, Kantonsspital, 4600 Olten, Schweiz
    Chirurg 73:370-4. 2002
    ..Although of histologically benign appearance, it infiltrates and destroys the surrounding tissue. There is a high risk of local recurrence and malignant transformation. The treatment of choice is wide surgical resection...
  84. ncbi Effect of anal epidermoid cancer-related viruses on the dendritic (Langerhans') cells of the human anal mucosa
    Iradj Sobhani
    Department of Gastroenterology and Oncology, Hopital Bichat Claude Bernard, Paris, France
    Clin Cancer Res 8:2862-9. 2002
    ..The incidence of anal cancer is high in patients with anal condyloma. HIV increases this risk. We analyzed anal mucosa from normal individuals and individuals with condyloma...
  85. ncbi Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy
    Cecile Ortholan
    Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France
    Int J Radiat Oncol Biol Phys 62:479-85. 2005
    ..To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey...
  86. ncbi Induction chemotherapy followed by radiotherapy in the treatment of anal cancer
    Dae Ho Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Korea
    Oncol Rep 10:101-4. 2003
    ..Induction chemotherapy followed by radiotherapy in patients with anal cancer is effective in terms of its response and preserving the anal sphincter without serious acute and late complications...
  87. ncbi [Prognosis of epidermoid anal carcinoma regression after conservative treatment]
    T S Odariuk
    Vopr Onkol 50:663-7. 2004
    ..015). ERUS uTNM staging is more effective in prognosis for RT and CRT and, therefore, should be recommended for preliminary management of epidermoid anal carcinoma...
  88. ncbi Chemoradiation for adenocarcinoma of the anus
    Michael Papagikos
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
    Int J Radiat Oncol Biol Phys 55:669-78. 2003
    ....
  89. ncbi Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index
    Arthur Hung
    Department of Radiation Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA
    Cancer 97:1195-202. 2003
    ..These rates are comparable to the best results reported with mitomycin-C and 5-FU. Without the normally severe toxicity, cisplatin-based therapy results in a wider therapeutic index...
  90. ncbi Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness
    Robson Ferrigno
    Department of Radiation Oncology, , , Brazil
    Int J Radiat Oncol Biol Phys 61:1136-42. 2005
    ..Local control was higher in patients treated with doses of more than 50 Gy at primary tumor. The high incidence of inguinal failure implies the need for elective RT in this region...
  91. ncbi Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA
    Danielle W Lu
    Lauren V. Ackerman Laboratory of Surgical Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA
    Mod Pathol 16:692-9. 2003
    ....
  92. ncbi Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients
    Lori A Panther
    Department of Internal Medicine, Division of Infectious Diseases, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 15:79-82, 85-6, 88, 91. 2005
    ..All HIV-positive patients with invasive cancer of the anal canal, particularly those with CD4+ cell counts greater than 200/microL and those receiving HAART, should be managed in the same manner as their HIV-negative counterparts...
  93. ncbi [Perianal Bowen's disease: a case report and review of the literature]
    A Bertagni
    UO di Chirurgia Generale II, , Ospedale GB Morgagni-L Pierantoni, Forl
    Tumori 89:16-8. 2003
    ..We report a case of a 50-years-old woman with recurrence of Bowen's disease associated with vulvar HPV infection and review the literature...
  94. ncbi [Epidermoid carcinomas of the anal canal treated with definitive radiation therapy in a series of 305 patients]
    E Deniaud-Alexandre
    , , 4, rue de la-Chine, 75020 Cedex 20, Paris, France
    Cancer Radiother 7:237-53. 2003
    ..However, chemoradiotherapy should be prefered to improve survival free of colostomy with a good anal sphincter function for tumors more than or equal to 2 cm in length and locally advanced tumors...
  95. ncbi Treatment of relapsing anal carcinoma
    G Tanum
    Department of Oncology, Norwegian Radium Hospital, Oslo
    Acta Oncol 32:33-5. 1993
    ..An abdominoperineal resection was performed on 9 of the 11 patients with local relapse. Of these, 6 patients were alive without evident disease after 3 years of observation...
  96. ncbi Risk factors associated with requiring a stoma for the management of anal cancer
    Wyn D Nguyen
    Department of Colon and Rectal Surgery, Baylor University Medical Center, Dallas, Texas, USA
    Dis Colon Rectum 47:843-6. 2004
    ..Toxicities from chemoradiotherapy do arise, but patients are not at increased risk for requiring a stoma...
  97. ncbi [Effectiveness of chemoradiotherapy for three cases of squamous cell anal carcinoma]
    Atsushi Takeno
    Dept. of Surgery, National Hospital Organization Osaka National Hospital
    Gan To Kagaku Ryoho 31:1870-2. 2004
    ..The prognosis of anal squamous cell carcinoma that received Cur B or C resection was extremely poor with a median survival time (MST) of 7 or 6 months. Chemoradiotherapy seems to be effective as the first line treatment...
  98. ncbi [Rationale and progress of the phase III trial: intensification of the treatment of locally advanced squamous cell carcinoma of the anal canal]
    D Peiffert
    Centre Alexis Vautrin, 6, Avenue de Bourgogne, 54511 Vandaeuvre les Nancy, France
    Cancer Radiother 7:100s-107s. 2003
    ..The results of the 101 first included patients are studied by an intermediate analyze. In July 2003, 222 patients were enrolled by 33 investigating centres out of the 350 planned patients until the end of the trial in December 2004...
  99. ncbi Bilateral leg amputation following chemoradiation for squamous carcinoma of the anus
    Tamasin K A Evans
    Radiother Oncol 73:110-1. 2004
  100. ncbi Neoadjuvant chemotherapy followed by radiotherapy in epidermoid carcinoma of anus
    Eui Kyu Chie
    Department of Therapeutic Radiology, Seoul National University College of Medicine, Korea
    Tumori 90:299-302. 2004
    ..CONCLUSIONS: Neoadjuvant chemotherapy with a cisplatin-based regimen rather than concurrent regimen plus radiotherapy may decrease complications without compromising survival or sphincter preservation...
  101. ncbi Activity of HspE7, a novel immunotherapy, in patients with anogenital warts
    Stephen E Goldstone
    Mount Sinai School of Medicine, New York, New York, USA
    Dis Colon Rectum 45:502-7. 2002
    ..The warts improved substantially but usually did not totally disappear within six months. Patient follow-up continues. A new randomized, placebo-controlled trial is underway to evaluate these findings...

Research Grants105 found, 100 shown here

  1. Strategies Against HPV Related Genital Diseases in Women
    Bradley Monk; Fiscal Year: 2006
    ..It is expected that Dr. Monk will have obtained extramural funding for both his laboratory and clinical studies by the end of the period of support requested. ..
  2. Effect of Oxidant Load on HPV Persistence and CIN (SIL)
    Anna Giuliano; Fiscal Year: 2007
    ..abstract_text> ..
  3. Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
    Jaffer A Ajani; Fiscal Year: 2010
    ..Our goal is to pave the way for a strategy in the future that will allow administration of effective therapy, improve safety, and preserve the esophagus in some patients. ..
  4. NATURAL HISTORY OF ANAL NEOPLASIA IN HIV-INFECTED MEN
    Joel Palefsky; Fiscal Year: 1993
    ..These studies may therefore provide valuable information relevant to other diseases as well, such as cancer of the cervix...
  5. Anal HPV Infection and ASIL in HIV+ and HIV- Women
    Joel Palefsky; Fiscal Year: 2006
    ..Knowledge of genes involved in ASIL pathogenesis may provide new approaches to therapy of both anal and cervical HSIL as well as markers for disease progression. ..
  6. NATURAL HISTORY OF ANAL NEOPLASIA IN HIV INFECTED MEN
    Joel Palefsky; Fiscal Year: 2002
    ....
  7. Anal HPV Infection and ASIL in HIV+ and HIV- Women
    Joel Palefsky; Fiscal Year: 2005
    ..Knowledge of genes involved in ASIL pathogenesis may provide new approaches to therapy of both anal and cervical HSIL as well as markers for disease progression. ..
  8. Anal Dysplasia in HIV+ and HIV- men
    Timothy Wilkin; Fiscal Year: 2006
    ..This study will help provide important new information on which groups of HIV+ men may benefit from screening and how HAART may modify this risk. ..
  9. The Epidemiologic Effects of HAART on HIV-related Anal Cancer and Anal Dysplasia
    Elizabeth Chiao; Fiscal Year: 2007
    ....
  10. BREAST CANCER AND GENE POLYMORPHISMS IN CHINESE WOMEN
    Chu Chen; Fiscal Year: 2003
    ..Our ultimate goal is to provide information to identify women at high risk of breast cancer, and to aid in the formulation of prevention strategies for these women. ..
  11. MOLECULAR EPIDEMIOLOGY OF LUNG CANCER
    Chu Chen; Fiscal Year: 2010
    ..g. Rosaceae fruits and Cruciferae vegetables), and food-derived nutrients (e.g. carotenoids, vitamin C, and vitamin E). ..
  12. Natural History of HPV Infection to Neoplasia
    Anna Barbara Moscicki; Fiscal Year: 2007
    ..Information garnered from this type of study will be critical in developing vaccine strategies and therapies as well as illuminating immune responses developed in the mucosal epithelium. ..
  13. Natural History of CIN2 in Adolescents
    Anna Barbara Moscicki; Fiscal Year: 2007
    ..S. and specifically assess how best to modify cytology-based screening, utilize HPV diagnostics, and tailor aoDrooriate follow-uo strategies for adolescents and vouna women diaanosed with CIN 2 ..
  14. Clinical & Cost Effectiveness of HPV Vaccination in the US
    Sue Goldie; Fiscal Year: 2009
    ....
  15. Breast and Prostate Cancer Patterns of Care
    Rosemary Cress; Fiscal Year: 2007
    ..What is learned about treatment quality and completeness can subsequently be used to improve the information in these registries so that they can become a resource for researchers evaluating quality of cancer care. ..
  16. Human papillomavirus as a risk factor for HIV infection
    PETER CHIN HONG; Fiscal Year: 2007
    ..If HPV-associated epithelial abnormalities are risk factors for HIV infection, then identification of such lesions may improve assessment of HIV transmission risk and could direct future interventions for HIV prevention. ..
  17. Planning Grant: Cancer Research Training in Morocco
    Anna Giuliano; Fiscal Year: 2009
    ..S. and in Morocco, and support cancer that will benefit the U.S. through elucidation of cancer risk factors and cancer disease progression.. ..
  18. Natural History of HPV Infection in Men: The HIM Study
    Anna R Giuliano; Fiscal Year: 2011
    ....
  19. Cidofovir for Perianal Dysplasia in HIV Patients
    Elizabeth Stier; Fiscal Year: 2006
    ..Novel treatments, such as topical cidofovir, may prevent pre-cancerous lesions from developing into cancer in HIV-infected patients. ..
  20. Natural History of HPV Infection in Men: The HIM Study
    Anna Giuliano; Fiscal Year: 2007
    ..abstract_text> ..
  21. Natural History of HPV Infection in Men: The HIM Study
    Anna R Giuliano; Fiscal Year: 2010
    ....
  22. ANTIOXIDANTS NUTRIENTS AMONG A BRAZILIAN POPULATION
    Anna Giuliano; Fiscal Year: 2002
    ..Results from this study will efficiently further our understanding of the role of antioxidant nutrients and cervical carcinogens. ..
  23. FOUR-CORNERS BREAST AND ENDOMETRIAL CANCER STUDY
    Anna Giuliano; Fiscal Year: 2002
    ..C-peptide, glycosylated hemoglobin, IGF-1, and IGFBP3 will be evaluated with respect to breast and endometrial cancer in a subset of women. ..
  24. Effect of Oxidant Load on HPV Persistence and CIN (SIL)
    Anna Giuliano; Fiscal Year: 2004
    ..abstract_text> ..
  25. HPV methylation: a biomarker of cervical lesion progress
    Anna Giuliano; Fiscal Year: 2003
    ..Results from this study may provide a novel biomarker for women at risk of progression of HPV infection to SIL. ..
  26. NATURAL HISTORY OF HPV IN TEENS--INFECTION TO NEOPLASIA
    Anna Barbara Moscicki; Fiscal Year: 1999
    ..The results from this study will be related to the prevention and education of pre-cancer lesions in young women as well as identifying a clinical model for the role of viruses in abnormal cellular development. ..
  27. NATURAL HISTORY OF HPV IN TEENS--INFECTION TO NEOPLASIA
    Anna Barbara Moscicki; Fiscal Year: 1993
    ..The results from this study will be related to the prevention and education of pre-cancer lesions in young women as well as identifying a clinical model for the role of viruses in abnormal cellular development...
  28. Natural History of CIN2 in Adolescents
    Anna Barbara Moscicki; Fiscal Year: 2005
    ..abstract_text> ..
  29. NATURAL HISTORY OF HPV--INFECTION TO NEOPLASIA
    Anna Barbara Moscicki; Fiscal Year: 2004
    ..The understanding of both local and systemic immune responses to initial and subsequent HPV infections may be key in vaccine or therapeutic developments. ..
  30. A San Francisco Street Youth Cohort: At Risk and HIV+
    Anna Barbara Moscicki; Fiscal Year: 2007
    ..We believe it is critical to continue to engage the high risk youth in the San Francisco Bay Area in clinical and behavioral research. ..